DF/BWCC in clinical affiliation with South Shore Hospital
DF/BWCC in clinical affiliation with South Shore Hospital
South Weymouth, Massachusetts, United States5 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 1 | 2026-09-24 | NCT03716180 | |
| Palbociclib After CDK and Endocrine Therapy (PACE) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-09-11 | NCT03147287 | |
| Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS) | Carcinoma, Lobular, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, Skin and Connective Tissue Diseases, adenocarcinoma, breast cancer, breast disorder, breast neoplasm, carcinoma, epithelial neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-06-23 | NCT02764541 | |
| Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 2 | 2026-04-29 | NCT04468061 | |
| Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, invasive breast carcinoma, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-01-15 | NCT04448886 |